Hepatitis C virus G1b infection decreases the number of small low-density lipoprotein particles

Chika Kinoshita1, Tomohisa Nagano1, Nobuyoshi Seki1

  • 1Chika Kinoshita, Tomohisa Nagano, Nobuyoshi Seki, Yoichi Tomita, Tomonori Sugita, Yuta Aida, Munenori Itagaki, Kenichi Satoh, Satoshi Sutoh, Hiroshi Abe, Yoshio Aizawa, Department of Gastroenterology and Hepatology Internal Medicine of Jikei University Katsushika Medical Center, Tokyo 125-8506, Japan.

Insights

Hepatitis C virus (HCV) G1b infection significantly lowers the particle numbers of medium, small, and very small low-density lipoprotein (LDL) particles. This finding highlights a specific impact of active HCV G1b infection on lipoprotein profiles.

Area of Science:

  • Virology
  • Lipid Metabolism
  • Biochemistry

Background:

  • Hepatitis C virus (HCV) infection is a global health concern.
  • Understanding the impact of HCV on host lipid metabolism is crucial for managing associated complications.
  • Previous studies have suggested alterations in lipoprotein profiles in HCV patients, but specific impacts of genotype 1b require further investigation.

Purpose of the Study:

  • To investigate the influence of hepatitis C virus (HCV) G1b infection on the particle number of various lipoproteins.
  • To determine if active HCV G1b infection is associated with specific changes in lipoprotein sub-fractions compared to sustained virologic response (SVR).

Main Methods:

  • Serum lipoprotein particle numbers were quantified in 173 Japanese subjects (82 active HCV G1b, 91 SVR) using high-performance liquid chromatography and a novel algorithm.
  • Cholesterol and triglyceride concentrations in lipoprotein fractions were measured using LipoSEARCH.
  • Multiple linear regression analysis was employed to assess the relationship between HCV G1b infection and lipoprotein particle numbers.

Main Results:

  • Active HCV G1b infection was associated with significantly lower numbers of total low-density lipoprotein (LDL) particles compared to the SVR group.
  • Specifically, the particle numbers of medium, small, and very small LDL sub-fractions were significantly reduced in individuals with active HCV G1b infection.
  • No significant differences were observed in very low-density lipoprotein (VLDL) or high-density lipoprotein (HDL) particle numbers, nor in large LDL particles, between the groups.

Conclusions:

  • Hepatitis C virus (HCV) G1b infection is associated with a significant decrease in the particle numbers of medium, small, and very small LDL.
  • These findings suggest a specific impact of active HCV G1b infection on LDL metabolism, independent of HDL and VLDL levels.
Abstract

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K
Viruses with RNA Genomes01:29

Viruses with RNA Genomes

RNA viruses are categorized into positive-strand, negative-strand, or double-stranded groups based on their genomic structure and replication mechanisms. This classification dictates how they exploit host cellular machinery for protein synthesis and replication. Some RNA viruses also utilize reverse transcription as part of their life cycle, further diversifying their replication strategies.Positive-Strand RNA VirusesPositive-strand RNA viruses have genomes that function directly as messenger...
1.2K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
312